HumanFirst accelerates patient-centered clinical trials by utilizing precision digital measures, including digital biomarkers and electronic Clinical Outcome Assessments (eCOA). This approach enhances data collection and patient engagement, addressing the inefficiencies in traditional trial methodologies.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional clinical trials often suffer from inefficient data collection methods and limited patient engagement, leading to delays and increased costs. The reliance on conventional methodologies hinders the ability to capture precise and continuous patient data, impacting the accuracy and effectiveness of trial outcomes.
Solution
HumanFirst, now part of ICON, addresses these challenges by providing precision digital measures, including digital biomarkers and electronic Clinical Outcome Assessments (eCOA), to enhance patient-centered clinical trials. Their approach focuses on improving data collection and boosting patient engagement, leading to more efficient and insightful trial results. The Atlas platform remains functional and reliable, offering a breadth and depth of evidence and insights for existing customers. ICON is working to further enhance the value users derive from Atlas, building out capabilities in collaboration with Mapi Research Trust.
Target Audience
The primary audience includes clinical research organizations, pharmaceutical companies, and researchers seeking to improve the efficiency and accuracy of clinical trials through digital health solutions.
Features
- Precision digital measures for enhanced data collection in clinical trials
- Digital biomarkers for continuous and objective patient monitoring
- Electronic Clinical Outcome Assessments (eCOA) for improved patient-reported outcomes
- Atlas platform providing a comprehensive view of trial data and insights